# Milliner platform

Turning an antibody into a drug means tuning binding, stability, aggregation and other properties that pull against one another, and lead optimization often takes months to years. Anthropic and BigHat had one researcher and Claude operate BigHat's automated lab via MCP to optimize one VHH and one single-chain Fv antibody across seven design rounds. In 10 weeks they synthesized and comprehensively tested 1,232 antibodies; the most improved variants of both bound their targets up to nine times more tightly, one reaching sub-nanomolar affinity, stayed stable in solution at temperatures up to 18°C higher, and aggregated far more slowly.

Turning an antibody into a drug means tuning binding, stability, aggregation and other properties that pull against one another, and lead optimization often takes months to years. Anthropic and BigHat had one researcher and Claude operate BigHat's automated lab via MCP to optimize one VHH and one single-chain Fv antibody across seven design rounds. In 10 weeks they synthesized and comprehensively tested 1,232 antibodies; the most improved variants of both bound their targets up to nine times more tightly, one reaching sub-nanomolar affinity, stayed stable in solution at temperatures up to 18°C higher, and aggregated far more slowly.